Association of potential salivary biomarkers with diabetic retinopathy and its severity in type-2 diabetes mellitus: a proteomic analysis by mass spectrometry

Chin Soon Chee, Khai Meng Chang, Mun Fai Loke, Voon Pei Angela Loo, Visvaraja Subrayan

Aim/hypothesis The aim of our study was to characterize the human salivary proteome and determine the changes in protein expression in 2 different stages of diabetic retinopathy with type-2 diabetes mellitus: (1) with non-proliferative diabetic retinopathy (NPDR) and (2) with proliferative diabetic retinopathy (PDR). Type-2 diabetes without diabetic retinopathy (XDR) was designated as control. **Method** In this study, 45 saliva samples were collected (15 samples from XDR control group, 15 samples from NPDR disease group and 15 samples from PDR disease group). Salivary proteins were extracted, reduced, alkylated, trypsin digested and labeled with iTRAQ before analyzing by Orbitrap fusion tribrid mass spectrometer. Proteins annotation, fold change calculation and statistical analysis were interrogated by Proteome Discoverer. Biological pathway analysis was performed by Ingenuity Pathway Analysis. Data are available via ProteomeXchange with identifiers PXD003723-PX003725. **Results** A total of 315 proteins were identified from the salivary proteome and 119 proteins were found to be differentially expressed. The differentially expressed proteins from the NPDR disease group and the PDR disease group were assigned to respective canonical pathways indicating increased LXR/RXR activation, FXR/RXR activation, acute phase response signaling, sucrose degradation V and regulation of actin-based motility by Rho in the PDR disease group compared to the NPDR disease group **Conclusions/Interpretation** Progression from non-proliferative to proliferative retinopathy in type-2 diabetic patients is a complex multi-mechanism and systemic process. Furthermore, saliva was shown to be a feasible alternative sample source for diabetic retinopathy biomarkers.

Association of potential salivary biomarkers with diabetic retinopathy and its severity in type-2 diabetes mellitus: a proteomic analysis by mass spectrometry

Chin Soon Chee [1], Khai Meng Chang [1], Mun Fai Loke [2], Angela Voon Pei Loo [1]*, Visvaraja Subrayan [1]

(1) Department of Ophthalmology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia

(2) Department of Medical Microbiology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia

*Corresponding author:
Angela Voon Pei Loo
Department of Ophthalmology
Faculty of Medicine
University of Malaya
50603 Kuala Lumpur
Malaysia
Phone: +603-79492060
Email: voonpei@um.edu.my

Abstract

Aim/hypothesis The aim of our study was to characterize the human salivary proteome and determine the changes in protein expression in 2 different stages of diabetic retinopathy with type-2 diabetes mellitus: (1) with non-proliferative diabetic retinopathy (NPDR) and (2) with proliferative diabetic retinopathy (PDR). Type-2 diabetes without diabetic retinopathy (XDR) was designated as control.

Method In this study, 45 saliva samples were collected (15 samples from XDR control group, 15 samples from NPDR disease group and 15 samples from PDR disease group). Salivary proteins were extracted, reduced, alkylated, trypsin digested and labeled with iTRAQ before analyzing by Orbitrap fusion tribrid mass spectrometer. Proteins annotation, fold change calculation and statistical analysis were interrogated by Proteome Discoverer. Biological pathway analysis was performed by Ingenuity Pathway Analysis. Data are available via ProteomeXchange with identifiers PXD003723-PX003725.

Results A total of 315 proteins were identified from the salivary proteome and 119 proteins were found to be differentially expressed. The differentially expressed proteins from the NPDR disease group and the PDR disease group were assigned to respective canonical pathways indicating increased LXR/RXR activation, FXR/RXR activation, acute phase response signaling, sucrose degradation V and regulation of actin-based motility by Rho in the PDR disease group compared to the NPDR disease group

Conclusions/Interpretation Progression from non-proliferative to proliferative retinopathy in type-2 diabetic patients is a complex multi-mechanism and systemic process. Furthermore, saliva was shown to be a feasible alternative sample source for diabetic retinopathy biomarkers.

Keywords: Diabetic retinopathy, salivary proteome, iTRAQ, LC/MS

Abbreviations

ACTB	Actin, cytoplasmic 1
AGC	Automatic gain control
AGE	Glycation end-products
ANXA1	Annexin A1
APOA1	Apolipoprotein A-I
C3	Complement 3
CAMP	Cathelicidin antimicrobial peptide
CAP1	Adenylyl cyclase-associated protein 1

76	CLU	Clusterin
77	ELANE	Neutrophil elastase
78	ENO1	Alpha-enolase isoform 1
79	EZR	Ezrin
80	FXR/RXR	Farnesoid X receptor/Retinoid X receptor
81	GAPDH	Glyceraldehyde-3-phosphate dehydrogenase isoform 2
82	GO	GO annotation
83	GSN	Gelsolin isoform d
84	HBA1/HBA2	Hemoglobin subunit alpha
85	HCD	Higher-energy collisional dissociation
86	HP	Haptoglobin isoform 2
87	HSPA1A/HSPA1B	Heat shock 70 kDa protein 1A/1B
88	HSPA8	Heat shock cognate 71 kDa protein isoform 1
89	iBRB	Inner blood retina barrier
90	IPA	Ingenuity Pathway Analysis
91	iTRAQ	Isobaric tag for relative and absolute quantitation
92	kV	kilovolt
93	LC-MS	Liquid chromatography- mass spectrometer
94	LCN1	Lipocalin-1 isoform 1
95	LCN2	Neutrophil gelatinase-associated lipocalin
96	LCP1	Plastin-2
97	LDHA	L-lactate dehydrogenase A chain isoform 3
98	LTF	lactotransferrin isoform 1
99	LXR/RXR	Liver X receptor/ Retinoid X receptor
100	MIF	Macrophage migration inhibitory factor
101	MMP9	Matrix metalloproteinase-9
102	MPO	Myeloperoxidase
103	MRP8/14	Myeloid-Related Protein-8/14
104	MS	Mass spectrometry
105	NPDR	Type-2 diabetes mellitus with non-proliferative diabetic retinopathy

106	PDR	Type-2 diabetes mellitus with proliferative diabetic retinopathy
107	PKM	Pyruvate kinase isozymes M1/M2 isoform c
108	PLTP	Phospholipid transfer protein isoform a
109	PRDX1	Peroxiredoxin-1
110	PRTN3	Profilin-1
111	S100A8	S100 calcium-binding protein A8
112	S100A9	S100 calcium-binding protein A9
113	SERPINA1	Alpha-1-antitrypsin
114	SIM	Single ion monitoring
115	SLPI	Antileukoproteinase
116	TIMP1	Metalloproteinase inhibitor 1
117	TLR-4	Toll-like receptor-4
118	TPM3	Tropomyosin alpha-3 chain isoform
119	XDR	Type-2 diabetes mellitus without diabetic retinopathy
120		
121		
122		
123		
124		
125		
126		
127		
128		
129		
130		
131		
132		
133		
134		
135		

136

137

138

139

140

141

Introduction

Early onset of type-2 diabetes mellitus has been devastating and a major epidemic across the world. Report shows that 7% of newly diagnosed type-2 diabetic patients in the U.S. have been diabetic for approximately 4-7 years before diagnosis (Rao et al. 2009). There is a very low global awareness and precaution on how to prevent type-2 diabetes. Patients with prolong type-2 diabetes without proper consultation and medication have a higher probability of developing complications such as diabetic retinopathy which can eventually lead to blindness.

Diabetic retinopathy is one of the most common and severe microvascular complications of type-2 diabetes. Symptoms of diabetic retinopathy were retinal ischemia and increased retinal vascular permeability which leads to vision loss or blindness ultimately. Diabetic retinopathy could be classified into two main stages: non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) in terms of the severity. The NPDR patients had lesions on the eye vasculature layer and vision would be lost if there was fluid in the central portion of the eyes (Csosz et al. 2012). PDR was literally characterized by pathological retinal vascular leakage (macular edema) and retinal neovascularization (Gao et al. 2008). There are several studies reported on the factors related to pathogenesis of PDR (Tarr et al. 2013), e.g., vascular endothelial growth factor for the proliferation and propagation of blood vessels in eyes, angiotensin-converting enzyme, insulin-like growth factor, angiopoietin, erythropoietin, placenta growth factor, advanced glycation end product, and antiangiogenic factors like pigment epithelium-derived factor.

The noninvasive nature and simple collection allows repetition and multiple collection of saliva that can potentially aid in early diagnosis, monitoring disease progression, or treatment responses with minimally trained personnel. This advantage of using saliva attracts investigators who are looking for an alternative body fluid to simplify diagnostic procedures (Giusti et al. 2007a; 2007b; Hu et al. 2007a; Peluso et al. 2007). Secretions from salivary glands, oral mucosa, periodontium, and oral microbiota all contribute to the final content of saliva. Saliva, a complex balance from local and systemic sources, allows for applications in the diagnosis not only for salivary gland disorders but also for oral diseases and systemic conditions (Caporossi et al. 2010; Good et al. 2007; Hu et al. 2007b; Lee et al. 2009). In our study, saliva samples from XDR, NPDR and PDR patient groups are selected as a diagnostic fluid to study the salivary proteome. Saliva offers several advantages over vitreous humor, tears and serum. The availability of saliva make it the simplest and non-invasive way of body fluid collection allowing repetitive collection. Saliva collection decreases the risk of contracting infectious diseases compared to other body fluids collection and it is convenient to obtain saliva from children or handicapped patients, in whom blood sampling could be inconvenient. Saliva is an ideal body fluid for the purpose of biomarker identification based on several decent studies. Castagnora et al (Castagnola et al. 2011) reported that there was existence of specific salivary biomarkers associated with a health or disease state. In the meanwhile, Shinkai et al (Shinkai et al. 2004) also reported that there was an altered saliva composition in type-2 diabetic patients. Hence, it is important to investigate the salivary proteome profiles for diabetic retinopathy complications. Moreover, biomarkers from salivary proteome of diabetic retinopathy are yet to be discovered.

In recent years, advancement in proteomic technology has invented plenty of instruments for proteomics research. A sophisticated mass spectrometer, the Orbitrap fusion tribrid mass spectrometer is used in our study to achieve our objective. The Orbitrap fusion tribrid mass

spectrometer, comprises of a mass filter, a collision cell, a high-field Oribitrap analyzer and a dual cell linear ion trap analyzer, offers high MS^2 acquisition speed of 20 Hz (Senko et al. 2013). We believe that this new system, with its fast scan rate, could provide more comprehensive proteome analysis within shorter time. The development of higher energy collision-induced dissociation (HCD) in the LTQ-Orbitrap has also overcome the 1/3 rule limitation that restricts the analysis of product ions with m/z values less than 25–30% of the precursor ion in traditional ion-trap instruments (Rauniyar et al. 2014). Limitations with analyzing biological samples of complex nature, such as the salivary proteome, are the masking of low-abundance proteins by the preponderance of a small number of highly abundant salivary proteins and the high dynamic range of such proteome that precludes the use of conventional proteomic strategies (Hu et al. 2005; 2007a). A method that has been proposed to largely overcome these deficits is isobaric labeling (iTRAQ: isobaric tags for absolute and relative quantitation) (Casado-Vela et al. 2010; Rauniyar et al. 2014). These isotope tags permit ready discrimination by mass spectrometry, thereby permitting comparative quantification to a reference sample in a multiplex manner and the examination of different samples in a single mass spectrometric analysis with good quantification precision. Hence, the ratio cutoff applied for significant protein change via the iTRAQ approach is lower than the cutoff applied for the label-free quantification approach (Rauniyar et al. 2014). This is the first attempt to analyze the salivary proteome profiles of type-2 diabetes complicated with diabetic retinopathy using the high resolution and accurate mass Orbitrap fusion tribrid mass spectrometer.

Methodology

Sample collection and processing

Saliva sample from 45 subjects with type-2 diabetes mellitus were collected. Subjects for this study were recruited from patients who visited the Eye clinic at the University of Malaya Medical Center (UMMC) during the period between November 2013 and April 2014. Patients older than 45 years old diagnosed with type-2 diabetes for more than 5 years with or without diabetic retinopathy were included in this study. All the patients were on oral medication for glycemic index control and /or dyslipidemia (none of them were on insulin therapy). The following patients were excluded from the study: (1) patients who had oral surgery or treatment within the past 3 months; (2) patients who had active gum bleeding; (3) patients with dry mouth (e.g. Sjögren's syndrome); (4) patients who had recent oral injury; (5)patients with history of malignancy, autoimmune diseases, Hepatitis/ HIV infection; (6) patients on any types of eye drops for active eye disease (e.g. glaucoma, conjunctivitis); (7) patients who had significant ocular medium opacities such as cataract or hazy cornea; (8) patients who had intravitreal injection and/or retinal laser treatment prior to diagnose for diabetic retinopathy; (9) patients with quiescent PDR and (10) smokers. Patients were classified by their severity of diabetic retinopathy according to the International Clinical Classification System for Diabetic Retinopathy and Diabetic Macular Edema by American Academy of Ophthalmology (Wilkinson et al. 2003). Diabetic retinopathy was graded through clinical fundus examination photography by two independent eye specialists. Subjects were grouped into three groups based on their clinical presentation: (1) type-2 diabetes without diabetic retinopathy (XDR) as control, (2) type-2 diabetes with non-proliferative diabetic retinopathy (NPDR) and (3) type-2 diabetes with

proliferative diabetic retinopathy (PDR) (Table 1). PDR patients with active neovascularization were included.

Subjects fasted overnight for at least 8 hours (except for drinking) prior to the collection of saliva samples. They were instructed to avoid drinks containing caffeine and alcohol for 12 hours and avoid vigorous physical activity for 4 hours prior to sample collection. In addition, they were also reminded to avoid brushing teeth 1 hour prior to sample collection and avoid applying lipstick. Saliva samples were collected between 9-10 a.m. The subjects were asked to rinse their mouths thoroughly with sterile water 10 minutes before sample collection, then to tilt their heads forward and allow saliva to flow into a sterile centrifuge tube until 5mL of saliva was collected. Saliva samples were spun at 8000 ×g for 20 min at 4 °C to spin down nuclei, cell debris and bacteria cells. The supernatant was then kept at -20 °C for subsequent analysis.

This study was approved by the Medical Ethics Committee of UMMC (Reference number: 1017.28) and written informed consent was obtained from the patients prior to samples collection.

Table 1 Demographic of subjects.

Proteins extraction

Salivary protein was extracted by acetone precipitation method as described by Vitorino et al (Vitorino et al. 2012) with modification. Saliva samples were precipitated by mixing with six volumes of pre-chilled acetone (Grade AR) (Friedemann Schmidt, Parkwood, Perth, Australia) and mixed by vortexing. Each sample was allowed to stand overnight at 4 °C. After incubation, all samples were centrifuged at 12000 ×g for 30 min. The supernatant and pellet were separated. The pellet was dried at room temperature.

Protein concentration

Protein concentration was determined using Bradford assay (Bio-Rad, Hercules, California USA) with bovine serum albumin (BSA) as standard (Bradford 1976). Protein standards and tests were prepared in triplicate.

Reduction, alkylation and trypsin digestion of salivary proteins

Reduction, alkylation and trypsin digestion of salivary proteins were carried out according to the method described by Ross et al (Ross et al. 2004) with modification. Briefly, 50 µg of salivary protein was suspended in 100 mmol/l triethylammonium bicarbonate (pH 8.5) (Sigma-Aldrich, St. Louis, Missouri, USA) and vortex to make sure the pellet was completely dissolved. Protein reduction was carried out by adding 10 mmol/l tris-(2-carboxyethyl)-phosphine (Sigma-Aldrich, St. Louis, Missouri, USA) and incubated at 60 ºC for 60 min. Reduced protein was subsequently alkylated with 20 mmol/l iodoacetamide (Bio-Rad, Hercules, California, USA) in the dark for 60

min at room temperature. Finally, the protein samples were digested with 1 μg of mass spectrometry grade porcine trypsin (Calbiochem, La Jolla, California, USA) at 37 ºC for 16-18 hours. The reaction was terminated by adding trifluoroacetic acid (Sigma-Aldrich, St. Louis, Missouri, USA) to the final concentration of 5% (v/v).

Isobaric tag for relative and absolute quantitation (iTRAQ) labeling of salivary peptides

Digested peptides samples were labeled using the iTRAQ 8Plex Multiplexing kit (AB Sciex, Foster city, California, USA) according to the manufacturer's protocol. Peptides from XDR, NPDR and PDR patient groups were labeled with isobaric tags 113, 114 and 115 respectively at room temperature for 4 hours. The reaction was quenched with 20 mmol/l Tris (pH 8.0) (Sigma-Aldrich, St. Louis, Missouri, USA). The contents of each iTRAQ reagent labeled sample tubes were combined.

Peptide purification and concentration

Pierce C18 Spin Column (Thermo Scientific, Rockford, Illinois, USA) was used to purify and concentrate the labeled peptides according to the manufacturer's protocol.

Liquid chromatography-mass spectrometer (LC-MS) analysis

Ten micrograms of salivary digest were separated on the EASY-nLC 1000 (Thermo Scientific, San Jose, California, USA) using the Acclaim PepMap C_{18} (3 μm, 75 μm x 50 cm) column (Thermo Scientific, San Jose, California, USA). Solvent A was HPLC-grade water with 0.1% (v/v) formic acid, and solvent B was HPLC grade acetonitrile with 0.1% (v/v) formic acid. Separation was performed with stepwise gradient (5-30% B for 185 min, 30-50% B for 20 min, 50-95% B for 20 min) at 300 nl/min over 225 min. MS data was generated using an Orbitrap fusion tribrid mass spectrometer (Thermo Scientific, San Jose, California, USA) operated with -2.5 kV (positive ions) applied to the central electrode. The mixture of isotopolog peptides were analyzed by combining scan events from two SIM modes. The first full time scan mode (MS) employed a scan range (m/z) of 380-2,000, Orbitrap resolution of 120,000, target automatic gain control (AGC) values of 200,000 and a maximum injection time of 50 milisec. The second scan mode, HCD (high energy collisional dissociation)-MS/MS was performed at the Quadrupole with the isolation width of 1.6 Th, HCD fragmentation with normalized collision energy of 35 %, Orbitrap resolution of 30,000, target AGC values of 50,000, and a maximum injection time of 60 milisec. Only precursors with charge state 2–7 were subjected to MS^2. Monoisotopic precursor selection and dynamic exclusion (70 sec duration, 10 ppm mass tolerance) were enabled. Analysis was carried out with 3 technical replications.

Data analysis

The raw data was processed using Proteome Discoverer version 1.4 (Thermo Scientific, San Jose, California, USA). MS/MS spectra were searched with Sequest engine against *Homo sapiens* database using the following parameters: full trypsin digest with maximum 2 missed cleavages, fixed modification carbamidomethylation of cysteine (+57.021 Da), variable modification oxidation of methionine (+15.995 Da) and iTRAQ 8-plex modification of lysine and peptide N termini (+304.205 Da). Precursor mass tolerance was 10 ppm and product ions fragment ion tolerance was 0.02 Da. Peptide spectral matches were validated using percolator based on q-values at a 1% false discovery rate. iTRAQ ratio reporting was pair wise: NPDR/XDR (114/113) and PDR/XDR (115/113).

Bioinformatic analysis of differential expressed proteins.

Differentially expressed proteins from NPDR and PDR patient groups were further analyzed using Ingenuity Pathway Analysis (IPA version 8.8) (Qiagen, Redwood, California, USA) to statistically determine the functions and pathways associated with each of the individual proteins. Accession number for each of the proteins and the fold change between NPDR and PDR groups relative to XDR group were tabulated. IPA utilized the Ingenuity Pathways Analysis Knowledge Base (IPA KB), a manually curated database of protein interactions from the literature, for analysis. A fold change cut-off of 1.5 was set to identify significant differentially regulated proteins. A list of networks and functional and canonical pathways were generated and the significance of the associations was assessed with the Fisher's exact test ($p < 0.05$).

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Vizcaíno et al. 2016) partner repository with the dataset identifier sPXD003723- PXD003725.

RESULT

Based on the criteria that at least one unique peptide and a minimum of two peptides match for protein identification, 315 proteins could be identified from the salivary proteome. The mean percentage of peptide coverage was 35.17% ± 2.55 ranging from 1.72% to 87.67%. The overall salivary proteome was annotated using GO annotation analysis facilitated by Proteome Discoverer version 1.4 and ProteinCenter database. Salivary proteins were assigned according to three different classifications: cellular component classification, biological process classification and molecular function classification. Of which, 19% were cytoplasmic proteins, 19% were extracellular proteins, 12% were membrane proteins and 11% were proteins localized in the nucleus (Figure A in S1 figure). Metabolic proteins comprised 15% of the proteins identified, 13% were involved in regulation of biological process and 12% were proteins that respond to stimulus (Figure B in S1 figure). As high as 29% of the proteins were involved in protein binding, 18% showed catalytic activities and 11% was involved in metal ion binding (Figure C in S1 figure).

For quantitative analysis, only proteins with complete labeled peptides were considered. iTRAQ data was expressed in pair ratio: NPDR vs XDR (iTRAQ 114/ iTRAQ 113) and PDR vs. XDR (iTRAQ 115/ iTRAQ 113). Only those with fold-change <0.5 or >2 were considered to be differentially expressed. A total of 119 proteins were found to be differentially expressed. Fig. 1 illustrates the comparison of the log ratio of the relative intensity (NPDR/XDR; PDR/XDR) for proteins commonly found in XDR, NPDR and PDR disease groups. Fig. 2 presents the comparison of the log ratio of the relative intensity (NPDR/XDR; PDR/XDR) for proteins unique to XDR and NPDR or PDR disease groups. Among those that are differentially expressed, 1 protein was un-regulated in NPDR and PDR compared to XDR disease groups. Eighty-two proteins were increased in PDR compared to XDR disease groups but decreased in NPDR in comparison to XDR disease groups. Two proteins were down-regulated in NPDR compared to XDR disease groups but not detected in PDR disease group. The remaining 34 proteins were increased in PDR relative to XDR disease groups but not found in NPDR disease group.

Fig. 1 Log ratio of relative intensity (NPDR/XDR; PDR/XDR) for proteins commonly found in XDR, NPDR and PDR disease groups.

Fig. 2 Log ratio of relative intensity (NPDR/XDR; PDR/XDR or proteins found exclusively in NPDR and PDR disease groups.

A total of 117 salivary proteins were increased in PDR disease group relative to XDR disease group. Eighty two increased salivary proteins in PDR disease group were decreased in NPDR disease group, 34 were not found in NPDR disease group and metalloproteinase inhibitor 1 precursor was increased in both PDR and NPDR disease groups. Table S1 lists the top 26 most up-regulated salivary proteins with a minimum fold change of 20 by relative protein abundance. Among the top 20 proteins that were increased in PDR disease group, 13% were predicted to respond to stimulus, 10% were predicted to regulate biological process, 9% were involved in metabolism, 8% were involved in cell organization and biogenesis and 8% were predicted to be involved in defense response (Figure B in S2 figure). Most of these proteins were predicted to have protein binding capability (28%) and 17% might have catalytic activity (Figure C in S2 figure). On the other hand, peroxiredoxin-1 and unconventional myosin-IXb isoform 2 were decreased in NPDR disease group (Table S2).

Twenty one interacting proteins and 1 highly increased protein (clusterin from NPDR disease group), together with 35 interacting proteins and 1 highly increased protein (tropomyosin alpha-3 chain isoform 2 from PDR disease group) (Table in S3 table) generated 3 protein-protein networks (Figure in S3 figure). Network (A) includes the diseases and functions of connective tissue disorders, immunological disease and inflammatory disease. Network (B) includes the diseases and functions of cellular movement, hematological system development and function and immune cell trafficking while Network (C) includes the diseases and functions of cellular growth and proliferation, cancer and carbohydrate metabolism. The top three canonical pathways with the highest –log (p-value) for NPDR disease group were LXR/RXR activation, glycolysis I and clathrin-mediated endocytosis signaling while for PDR group the pathways were LXR/RXR activation, glycolysis I and FXR/RXR activation. Comparison between the differentially

expressed proteins from NPDR and PDR disease groups in different canonical pathways indicated increased LXR/RXR activation, FXR/RXR activation, acute phase response signaling, sucrose degradation V and regulation of actin-based motility by Rho in PDR disease group compared to NPDR disease group (Fig 3).

Fig. 3 Canonical pathways comparative studies in differentially expressed proteins from NPDR and PDR groups.

Discussion

To the best of our knowledge, the salivary proteome of diabetic retinopathy has not yet been characterized. Among top increased proteins in the PDR group, 8% were predicted to be defense proteins and 9% were metabolic proteins suggesting that the expression of salivary defense and metabolic proteins is related to diabetic retinopathy. This is consistent with the report by Fernandez-Real and Pickup (Fernandez-Real & Pickup 2008) that defense response proteins were elevated in type-2 diabetic patients and this gradually led to surging of metabolic proteins. Most of these defense response proteins that were increased in PDR are involved with pro-inflammatory immune response and many had previously been reported to be associated with diabetes mellitus. Such defense response proteins include S100-A9 (Cabras et al. 2010), alpha-2-macroglobulin-like protein 1 (James et al. 1980), neutrophil elastase (Collier et al. 1989), alpha-1-antitrypsin (SERPINA1) (Kalis et al. 2010), cystatin-C (Reutens et al. 2013) and macrophage migration inhibitory factor (MIF) (Tashimo et al. 2004). Heterodimer of S100-A9 and S100-A8 known as myeloid-related protein-8/14 (MRP8/14) binds to receptor for advanced glycation end-products and Toll-like receptor-4 (TLR-4) thereby initiating the intracellular inflammatory signaling cascade (Caseiro et al. 2013). Alpha 2-macroglobulin has been suggested to be a potential biomarker for diabetic retinopathy and other diabetic complications (Lu et al. 2013). Neutrophil elastase was reported to be a marker for the development of diabetic angiopathy (Piwowar et al. 2000). Neutrophil releases neutrophil elastase that enhances inflammatory responses. Alpha-1-antitrypsin (SERPINA1) can suppress apoptosis of pancreatic β-cells that promote insulin secretion (Kalis et al. 2010). A novel immune system regulatory pathway involving SERPINA1 and complement 3 (C3) was unveiled recently (Sahu & Lambris 2001). Activation of C3 promotes phagocytosis, supports local inflammatory responses against pathogens and initiates the humoral immune response; on the other hand, its activation leads to host cell damage. However, binding of SERPINA1 to C3 inhibits and regulates the cleavage and activation of C3 during inflammation. MIF produce by T lymphocytes and macrophage can initiate local inflammation through the inhibition of the random movement of macrophage and enhance their adhesion (Mitamura et al. 2000). Capillary occlusion can be caused by the natural tendency of leucocytes and macrophages to adhere to endothelium that eventually results in retinal ischemia seen in diabetic retinopathy (Schroder et al. 1991). MIF may play a role during the proliferative phase of diabetic retinopathy by activating and retaining intraocular macrophage. Furthermore, MIF interacts with peroxiredoxin-1 by reducing tautomerase and oxidoreductase activities of MIF and inhibits the activity of peroxiredoxin-1 (Kudrin & Ray 2008). Our result show that peroxiredoxin-1 was decreased in NPDR and not found in PDR that was in line with the result reported by Rao et al (Rao et al. 2009).

The up-regulation of BPI fold-containing family A member 1/2, BPI fold-containing family B member 2 and neutrophil gelatinase-associated lipocalin in the PDR patient group suggested that innate immune response might also be involved in PDR. This might also suggest the involvement of microbial agents in PDR pathogenesis. Binding of BPI to endotoxin of Gram-negative bacteria outer membrane could trigger sub-lethal and lethal effects on the bacteria and neutralize the activity of endotoxin (Schultz et al. 2007). Myeloperoxidase (MPO) and lactotransferrin isoform 1 (LTF) are abundantly expressed in neutrophil granulocytes with antioxidant, anticarcinogenic, antibacterial effects, implying an important role in innate immunity. During the oxidative burst of activated neutrophils, MPO utilize hydrogen peroxide and chloride anion to generate a highly reactive and cytotoxic product, hydrochlorous acid which are used by bactericidal (Mutze et al. 2003). Protein-protein networks analysis revealed that cellular target of LTF is MPO, to which LTF bind and inhibit MPO. Neutrophil gelatinase-associated lipocalin was demonstrated to be an early biomarker for diabetic nephropathy (Bolignano et al. 2009). In addition, neutrophil gelatinase-associated lipocalin is an iron-binding protein that may inhibit the growth of bacteria by depleting the iron source of bacteria (Cherayil 2011).

In addition, neutrophil gelatinase-associated lipocalin can also activate pro matrix metalloproteinase-9 (MMP-9) (Tschesche et al. 2001). Hyperglycemia-induced activation of MMP-9 promotes apoptosis of retinal capillary cells and can result in development of diabetic retinopathy (Kowluru 2010). Interestingly, metalloproteinase inhibitor 1, an inhibitor of MMP-9, was found to be increased in both NPDR and PDR patients. In contrast, MMP-9 was low in XDR patients. Florys et al (Florys et al. 2006) reported that high blood glucose concentration could induce the expression of metalloproteinase inhibitor 1. Thus, our results suggest that metalloproteinase inhibitor 1 may influence the development of diabetic retinopathy and combined with high levels of MMP-9 may drive the progression towards the proliferative phase.

The retina is rich in unsaturated fatty acid, rapid oxygen uptake and glucose oxidation rate compared to other areas of the human body that renders the retina highly susceptible to oxidative stress. Heme is highly toxic due to its ability to cause protein aggregation and produce lipid peroxide from lipid peroxidation that could contribute to oxidative stress. Hemopexin functions as a scavenger of heme. The finding of high level of hemopexin in the saliva of PDR patients supported the hypothesis that hyperglycemia, changes in the redox homeostasis and oxidative stress are key pathogenic events in diabetic retinopathy (Kowluru & Chan 2007). Glycation end-products (AGEs) are produced by non-enzymatic glycation reactions of amino groups, lipids and DNA with glucose and its formation is an important pathogenic mechanism in diabetic retinopathy. AGEs have been linked to the breakdown of the inner blood retina barrier (iBRB) during diabetic retinopathy by modulating the expression of vasopermeability factor (Amin et al. 1997). Galectin-3-binding protein, an AGE-binding protein, can enhance the iBRB dysfunction in diabetes and play a significant role in AGE-related pathophysiology during diabetic retinopathy (Pugliese et al. 2000). Galectin-3-binding protein was also presented in relatively high abundance in PDR patients. High abundance of clusterin has been reported in vitreous humor of PDR patients (Gao et al. 2008). Thus, it is not surprising that our data also shows an unprecedented high abundance of clusterin in the saliva of PDR patients. Clusterin is believed to promote angiogenesis or vascular permeability, which contributes to the pathogenesis of diabetic retinopathy (Wang et al. 2013).

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), alpha-enolase isoform 1 (ENO1) and pyruvate kinase isozymes M1/M2 isoform c (PKM) are typical enzymes found in saliva that are involved in glycolysis and gluconeogenesis. Although GAPDH is a glycolytic enzyme, it has also been proven to have multiple cytoplasmic, membrane, and nuclear functions. Saunders et al (Saunders et al. 1997) reported that GAPDH was a major intracellular messenger mediating apoptosis of cells and GAPDH translocation to the nucleus was considered a crucial step in glucose-induced apoptosis of retinal Muller cells. Moreover, the role of GADPH in the development and progression of diabetic retinopathy has been investigated by Kanwar & Kowluru (Kanwar & Kowluru 2009).

LXR/RXR activation, FXR/RXR activation, clathrin-mediated endocytosis signaling, acute phase response signaling and regulation of actin-based motility by Rho are highly associated with the pathogenesis and progression of diabetic retinopathy. Activation of liver X receptor (LXR) promotes reverse cholesterol transport and suppressed inflammatory response which in turn improve and inhibit the progression of diabetic retinopathy (Hazra et al. 2012). Retinoid X receptor (RXR) is known to be associated with the progression of diabetic retinopathy (Roy et al. 2009), with RXR activation playing a key role in inhibiting high-glucose-induced oxidative stress, systemic lipid and glucose metabolism, energy homeostasis, and inflammatory control. Role of farnesoid X receptor (FXR) in relation to diabetic retinopathy had not been reported so far, however, the role of FXR in diabetic nephropathy (Wang et al. 2010) and atherosclerotic lesion formation (Hartman et al. 2009) were well established. FXR is involved in microvascular or macrovascular complication of diabetes; hence, FXR may be related to the pathogenesis of diabetic retinopathy. Clathrin-mediated endocytosis is involved in the internalization of the ligand-receptor complex through clathrin-coated vesicles that initialize the intracellular signal transduction cascade in response to the stimulus. AGEs are known to accumulate within the neural retina of diabetics but the effect on neural dysfunction and depletion during retinopathy was poorly investigated (Stitt 2003). Retinal microvascular endothelial cells express AGE-receptor and mediate endocytic uptake of AGEs eventually leads to increased retinal vascular cells toxicity, affecting capillary function (Stitt 2003). Mizuno et al (Mizuno et al. 2010) reported that cellular degeneration, remodeling and cell death leading to emerging of new blood vessels which was observed in PDR was the consequence of excessive glutamate up-take by retinal vascular endothelial cells. As expected, acute phase response signaling pathway had played a causative role in the pathogenesis of diabetic retinopathy. Acute phase response is generally considered an adaptive response that restores homeostasis. However, excessive or persistent overexpression of acute-phase proteins can lead to tissue and organ damage (Gerhardinger et al. 2005). GTPases of the Rho family regulate the interaction between cells and extracellular matrix resulting in angiogenesis, vascular permeability, leukocyte migration and platelet formation *in vivo* In the early stage of angiogenesis, GTPase Rho facilitates the endothelial cell retraction and release of junctional complex simultaneously further facilitating the vascular leakage (Cheresh & Stupack 2008). Neovasculation is the main event in the proliferative stage of diabetic retinopathy and GTPase Rho may be a key regulator enzyme in the early stage of angiogenesis. Comparing this profile of vitreous (Gao et al. 2008; Wang et al. 2013; Yamane et al. 2003; Yu et al. 2008), similarities were noted in Table 2. This demonstrates that local (vitreous) changes in protein levels associated with pathogenesis and progression of diabetic retinopathy may be reflected systemically in the saliva.

As other microvascular complications of diabetes also progress with inflammatory processes, serum creatinine was measured (Table 1) to exclude patients with severe diabetic nephropathy. However, patients with non-detectable microvascular complications were not excluded, which is a limitation of our study. Furthermore, although patients with detectable poor oral hygiene were excluded, it is not possible to rule out patients with mild salivary gland inflammation.

In conclusion, the progression from non-proliferative to proliferative retinopathy in type-2 diabetic patients is a complex multi-mechanism and systemic process (Fig 4). These proteins may also be potential salivary biomarkers that correlate with progressive stages of diabetic retinopathy. Thus, saliva may be a convenient and less invasive alternative sample to vitreous humor, tear and serum for diabetic retinopathy protein biomarker development.

Table 2 Proteins associated with NPDR and PDR that were reported in vitreous.

Fig. 4 Summary of pathogenetic mechanism for non-proliferative diabetic retinopathy and proliferative diabetic retinopathy and the functional pathways involved.

Acknowledgement

The authors would like to thank Mr. HT Cheah (Engineer of Orbitrap fusion tribrid mass spectrometer) for his technical assistance with mass spectrometer setting, optimization, and data analysis.

References

Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW. 1997. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. *Investigative Ophthalmology & Visual Science* 38(1):36-47.

Bolignano D, Lacquaniti A, Coppolino G, Donato V, Fazio MR, Nicocia G, Buemi M. 2009. Neutrophil Gelatinase-Associated Lipocalin as an Early Biomarker of Nephropathy in Diabetic Patients. *Kidney & Blood Pressure Research* 32(2):91-98. doi: 10.1159/000209379.

Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Analytical Biochemistry* 72:248-254.

Cabras T, Pisano E, Mastinu A, Denotti G, Pusceddu PP, Inzitari R, Fanali C, Nemolato S, Castagnola M, Messana I. 2010. Alterations of the Salivary Secretory Peptidome Profile in Children Affected by Type 1 Diabetes. *Molecular & Cellular Proteomics* 9(10):2099-2108. doi: 10.1074/mcp.M110.001057.

Caporossi L, Santoro A, Papaleo B. 2010. Saliva as an analytical matrix: state of the art and application for biomonitoring. *Biomarkers* 15(6):475–487. doi: 10.3109/1354750X.2010.481364.

Casado-Vela J, Martínez-Esteso MJ, Rodriguez E, Borrás E, Elortza F, Bru-Martínez R. 2010. iTRAQ-based quantitative analysis of protein mixtures with large fold change and dynamic range. *Proteomics* 10(2):343-347. doi: 10.1002/pmic.200900509.

Caseiro A, Ferreira R, Padrao A, Quintaneiro C, Pereira A, Marinheiro R, Vitorino R, Amado F. 2013. Salivary proteome and peptidome profiling in type 1 diabetes mellitus using a quantitative approach. *Journal of Proteome Research* 12(4):1700-1709. doi: 10.1021/pr3010343.

Castagnola M, Picciotti PM, Messana I, Fanali C, Fiorita A, Cabras T, Calo L, Pisano E, Passali GC, Iavarone F, Paludetti G, Scarano E. 2011. Potential applications of human saliva as diagnostic fluid. *Acta Otorhinolaryngologica Italica* 31(6):347-357.

Cherayil BJ. 2011. The role of iron in the immune response to bacterial infection. *Immunologic Research* 50(1):1-9. doi: 10.1007/s12026-010-8199-1.

Cheresh DA, Stupack DG. 2008. Regulation of angiogenesis: apoptotic cues from the ECM. *Oncogene* 27(48):6285-6298. doi: 10.1038/onc.2008.304.

Collier A, Jackson M, Bell D, Patrick AW, Matthews DM, Young RJ, Clarke BF, Dawes J. 1989. Neutrophil Activation Detected by Increased Neutrophil Elastase Activity in Type-1 (Insulin-Dependent) Diabetes-Mellitus. *Diabetes Research Clinical and Experimental* 10(3):135-138.

Csosz E, Boross P, Csutak A, Berta A, Toth F, Poliska S, Torok Z, Tozser J. 2012. Quantitative analysis of proteins in the tear fluid of patients with diabetic retinopathy. *Journal of Proteomics* 75(7):2196-2204. doi: 10.1016/j.jprot.2012.01.019.

Fernández -Real JM, Pickup JC. 2008. Innate immunity, insulin resistance and type 2 diabetes. *Trends in Endocrinology and Metabolism* 19(1):10-16. doi: 10.1016/j.tem.2007.10.004.

Florys B, Głowińska B, Urban M, Peczyńska J. 2006. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes]. *Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw* 12:(3)184-189.

Gao BB, Chen XH, Timothy N, Aiello LP, Feener EP. 2008. Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. *Journal of Proteome Research* 7(6):2516-2525. doi: 10.1021/Pr800112g.

Gerhardinger C, Costa MB, Coulombe MC, Toth I, Hoehn T, Grosu P. 2005. Expression of acute-phase response proteins in retinal Muller cells in diabetes. *Investigative Ophthalmology & Visual Science* 46(1):349-357. doi: 10.1167/Iovs.04-0860

588 Giusti L, Baldini C, Bazzichi L, Ciregia F, Tonazzini I, Mascia G, Giannaccini G, Bombardieri S, Lucacchini A.
589 2007a. Proteome analysis of whole saliva: a new tool for rheumatic diseases—the example of
590 Sjögren's syndrome. *Proteomics* 7(10):1634–1643.
591 Giusti L, Bazzichi L, Baldini C, Ciregia F, Mascia G, Giannaccini G, Del Rosso M, Bombardieri S, Lucacchini
592 A. 2007b. Specific proteins identified in whole saliva from patients with diffuse systemic
593 sclerosis. *The Journal of Rheumatology* 34(10):2063–2069.
594 Good DM, Thongboonkerd V, Novak J, Bascands JL, Schanstra JP, Coon JJ, Dominiczak A, Mischak H. 2007.
595 Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in
596 the future. *Journal of Proteome Research* 6(12):4549–4555.
597 Hartman HB, Gardell SJ, Petucci CJ, Wang SG, Krueger JA, Evans MJ. 2009. Activation of farnesoid X
598 receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE(-/-) mice. *Journal of Lipid*
599 *Research* 50(6):1090-1100. doi: 10.1194/jlr.M800619-JLR200.
600 Hazra S, Rasheed A, Bhatwadekar A, Wang XX, Shaw LC, Patel M, Caballero S, Magomedova L, Solis N,
601 Yan YQ, Wang WD, Thinschmidt JS, Verma A, Li QH, Levi M, Cummins CL, Grant MB. 2012. Liver X
602 Receptor Modulates Diabetic Retinopathy Outcome in a Mouse Model of Streptozotocin-
603 Induced Diabetes. *Diabetes* 61(12):3270-3279. doi: 10.2337/Db11-1596.
604 Hu S, Wang J, Meijer J, Leong S, Xie Y, Yu T, Zhou H, Henry S, Vissink A, Pijpe J, Kallenberg C, Elashoff D,
605 Loo JA, Wong DT. 2007b. Salivary proteomic and genomic biomarkers for primary Sjögren's
606 syndrome. *Arthritis Rheumatism* 56(11):3588–3600.
607 Hu S, Loo JA, Wong DT. 2007a. Human saliva proteome analysis and disease biomarker discovery. *Expert*
608 *Review of Proteomics* 4(4):531–538.
609 Hu S, Xie Y, Ramachandran P, Ogorzalek Loo RR, Li Y, Loo JA, Wong DT. 2005. Large-scale identification of
610 proteins in human salivary proteome by liquidchromatography/mass spectrometry and two-
611 dimensional gel electrophoresis-mass spectrometry. *Proteomics* 5(6):1714-1728.
612 James K, Merriman J, Gray RS, Duncan LJ, Herd R. 1980. Serum alpha 2-macroglobulin levels in diabetes.
613 *Journal of Clinical Pathology* 33(2):163-166.
614 Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD. 2005. Matrix metalloproteinases and diabetic
615 vascular complications. *Angiology* 56(2):173-189.
616 Kalis M, Kumar R, Janciauskiene S, Salehi A, Cilio CM. 2010. Alpha 1-antitrypsin enhances insulin
617 secretion and prevents cytokine-mediated apoptosis in pancreatic beta-cells. *Islets* 2(3):185-189.
618 doi: 10.4161/isl.2.3.11654.
619 Kanwar M, Kowluru RA. 2009. Role of Glyceraldehyde 3-Phosphate Dehydrogenase in the Development
620 and Progression of Diabetic Retinopathy. *Diabetes* 58(1):227-234. doi: 10.2337/Db08-1025.
621 Kowluru RA. 2010. Role of Matrix Metalloproteinase-9 in the Development of Diabetic Retinopathy and
622 Its Regulation by H-Ras. *Investigative Ophthalmology & Visual Science* 51(8):4320-4326. doi:
623 10.1167/iovs.09-4851
624 Kowluru RA, Chan PS. 2007. Oxidative Stress and Diabetic Retinopathy. *Experimental Diabetes Research*
625 2007:43603. doi: 10.1155/2007/43603.
626 Kudrin A, Ray D. 2008. Cunning factor: macrophage migration inhibitory factor as a redox-regulated
627 target. *Immunology and Cell Biology* 86(3):232-238. doi: 10.1038/sj.icb.7100133.
628 Lee JM, Garon E, Wong DT. 2009. Salivary diagnostics. *Orthodontics and Craniofacial Research*
629 12(3):206–211. doi: 10.1111/j.1601-6343.2009.01454.x.
630 Lu CH, Lin ST, Chou HC, Lee YR, Chan HL. 2013. Proteomic analysis of retinopathy-related plasma
631 biomarkers in diabetic patients. *Archives of Biochemistry and Biophysics* 529(2):146-156. doi:
632 10.1016/j.abb.2012.11.004.

633 Mitamura Y, Takeuchi S, Matsuda A, Tagawa Y, Mizue Y, Nishihira J. 2000. Macrophage migration
634 inhibitory factor levels in the vitreous of patients with proliferative diabetic retinopathy. *British*
635 *Journal of Ophthalmology* 84(6):636-639. Doi 10.1136/Bjo.84.6.636.
636 Mizuno F, Barabas P, Krizaj D, Akopian A. 2010. Glutamate-induced internalization of Ca(v)1.3 L-type
637 Ca2+channels protects retinal neurons against excitotoxicity. *The Journal of Physiology* 588(Pt
638 6):953-966. doi: 10.1113/jphysiol.2009.181305.
639 Mütze S, Hebling U, Stremmel W, Wang J, Arnhold J, Pantopoulos K, Mueller S. 2003. Myeloperoxidase-
640 derived hypochlorous acid antagonizes the oxidative stress-mediated activation of iron
641 regulatory protein 1. *Journal of Biological Chemistry* 278(42):40542-40549. doi:
642 10.1074/jbc.M307159200.
643 Peluso G, De Santis M, Inzitari R, Fanali C, Cabras T, Messana I, Castagnola M, Ferraccioli GF. 2007.
644 Proteomic study of salivary peptides and proteins in patients with Sjögren's syndrome before
645 and after pilocarpine treatment. *Arthritis and Rheumatism.* 56(7):2216–2222.
646 Piwowar A, Knapik-Kordecka M, Warwas M. 2000. Concentration of leukocyte elastase in plasma and
647 polymorphonuclear neutrophil extracts in type 2 diabetes. *Clinical Chemistry and Laboratory*
648 *Medicine* 38(12):1257-1261. doi: 10.1515/Cclm.2000.198.
649 Pugliese G, Pricci F, Leto G, Amadio L, Iacobini C, Romeo G, Lenti L, Sale P, Gradini R, Liu FT, Di Mario U.
650 2000. The diabetic milieu modulates the advanced glycation end product-receptor complex in
651 the mesangium by inducing or upregulating galectin-3 expression. *Diabetes* 49(7):1249-1257. doi:
652 10.2337/diabetes.49.7.1249.
653 Rao PV, Reddy AP, Lu X, Dasari S, Krishnaprasad A, Biggs E, Roberts CT, Nagalla SR. 2009. Proteomic
654 identification of salivary biomarkers of type-2 diabetes. *Journal of Proteome Research* 8(1):239-
655 245. 10.1021/pr8003776
656 Rauniyar N, Yates JR 3rd. 2014. Isobaric labeling-based relative quantification in shotgun proteomics.
657 *Journal of Proteome Research* 13(12):5293-309. doi: 10.1021/pr500880b.
658 Reutens AT, Bonnet F, Lantieri O, Roussel R, Balkau B, Epidemiological Study on the Insulin Resistance
659 Syndrome Study Group. 2013. The association between cystatin C and incident type 2 diabetes is
660 related to central adiposity. *Nephrology, Dialysis, Transplantation* 28(7):1820-1829. doi:
661 10.1093/ndt/gfs561.
662 Ross PL, Huang YLN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels
663 S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A, Pappin DJ. 2004.
664 Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric
665 tagging reagents. *Molecular & Cellular Proteomics* 3(12):1154-1169. doi:
666 10.1074/mcp.M400129-MCP200.
667 Roy MS, Hallman M, Fu YP, Machado M, Hanis CL. 2009. Assessment of 193 Candidate Genes for
668 Retinopathy in African Americans With Type 1 Diabetes. *Archives of Ophthalmology* 127(5):605-
669 612. doi: 10.1001/archophthalmol.2009.48.
670 Sahu A, Lambris JD. 2001. Structure and biology of complement protein C3, a connecting link between
671 innate and acquired immunity. *Immunological Reviews* 180:35-48. doi: 10.1034/j.1600-
672 065X.2001.1800103.x
673 Saunders PA, ChaleckaFranaszek E, Chuang DM. 1997. Subcellular distribution of glyceraldehyde-3-
674 phosphate dehydrogenase in cerebellar granule cells undergoing cytosine arabinoside-induced
675 apoptosis. *Journal of Neurochemistry* 69(5):1820-1828.
676 Schröder S, Palinski W, Schmid-Schönbein GW. 1991. Activated Monocytes and Granulocytes, Capillary
677 Nonperfusion, and Neovascularization in Diabetic-Retinopathy. *American Journal of Pathology*
678 139(1):81-100.

679 Schultz H, Hume J, Zhang DS, Gioannini TL, Weiss JP. 2007. A novel role for the bactericidal/permeability
680 increasing protein in interactions of gram-negative bacterial outer membrane Blebs with
681 dendritic cells. *Journal of Immunology* 179(4):2477-2484.
682 Senko, MW, Remes PM, Canterbury JD, Mathur R, Song Q, Eliuk SM, Mullen C, Earley L, Hardman H,
683 Blethrow JD, Bui H, Specht A, Lange O, Denisov E, Makarov A, Horning S, Zakrouskov V. 2013.
684 Novel parallelized quadrupole/linear ion trap/orbitrap tribrid mass spectrometer improves
685 proteome coverage and peptide identification rates. *Analytical Chemistry* 85(24):11710-11714.
686 doi: 10.1021/ac403115c.
687 Shinkai RSA, Cornell JE, Hatch JP, Yeh CK. 2004. Intraoral tactile sensitivity in adults with diabetes.
688 *Diabetes Care* 27(4):869-873. doi: 10.2337/diacare.27.4.869.
689 Stitt AW. 2003. The role of advanced glycation in the pathogenesis of diabetic retinopathy. *Experimental*
690 *and Molecular Pathology* 75(1):95-108. doi: 10.1016/S0014-4800(03)00035-2.
691 Tashimo A, Mitamura Y, Nagai S, Nakamura Y, Ohtsuka K, Ohtsuka K, Mizue Y, Nishihira J. 2004. Aqueous
692 levels of macrophage migration inhibitory factor and monocyte chemotactic protein-1 in
693 patients with diabetic retinopathy. *Diabetic Medicine* 21(12):1292-1297.
694 Tarr JM, Kaul K, Chopra M, Kohner EM, Chibber R. 2013. Pathophysiology of diabetic retinopathy. *ISRN*
695 *Ophthalmology* 2013:343560. doi: 10.1155/2013/343560.
696 Tschesche H, Zolzer V, Triebel S, Bartsch S. 2001. The human neutrophil lipocalin supports the allosteric
697 activation of matrix metalloproteinases. *European Journal of Biochemistry* 268(7):1918-1928. doi:
698 10.1046/j.1432-1327.2001.02066.x.
699 Vitorino R, Barros AS, Caseiro A, Ferreira R, Amado F. 2012. Evaluation of different extraction
700 procedures for salivary peptide analysis. *Talanta* 94:209-215. doi: 10.1016/j.talanta.2012.03.023.
701 Vizcaíno JA, Csordas A, del-Toro N, Dianes JA, Griss J, Lavidas I, Mayer G, Perez-Riverol Y, Reisinger F,
702 Ternent T, Xu QW, Wang R, Hermjakob H. 2016. 2016 update of the PRIDE database and related
703 tools. *Nucleic Acids Research* 44(D1):D447-D456. doi: 10.1093/nar/gkv1145.
704 Wang H, Feng L, Hu JW, Xie CL, Wang F. 2013. Differentiating vitreous proteomes in proliferative
705 diabetic retinopathy using high-performance liquid chromatography coupled to tandem mass
706 spectrometry. *Experimental Eye Research* 108:110-119. doi: 10.1016/j.exer.2012.11.023.
707 Wang XX, Jiang T, Shen Y, Caldas Y, Miyazaki-Anzai S, Santamaria H, Urbanek C, Solis N, Scherzer P, Lewis
708 L, Gonzalez FJ, Adorini L, Pruzanski M, Kopp JB, Verlander JW, Levi M. 2010. Diabetic
709 Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X
710 Receptor Activation in a Type 1 Diabetes Model. *Diabetes* 59(11):2916-2927. doi: 10.2337/Db10-
711 0019.
712 Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R,
713 Verdaguer JT, Global Diabetic Retinopathy Project Group. 2003. Proposed international clinical
714 diabetic retinopathy and diabetic macular edema disease severity scales. *Ophthalmology*
715 110(9):1677-1682. doi: 10.1016/S0161-6420(03)00475-5.
716 Yamane K, Minamoto A, Yamashita H, Takamura H, Miyamoto-Myoken Y, Yoshizato K, Nabetani T,
717 Tsugita A, Mishima HK. 2003. Proteome analysis of human vitreous proteins. *Molecular &*
718 *Cellular Proteomics* 2(11):1177-1187. doi: 10.1074/mcp.M300038-MCP200.
719 Yu J, Liu F, Cui SJ, Liu Y, Song ZY, Cao H, Chen FE, Wang WJ, Sun T, Wang F. 2008. Vitreous proteomic
720 analysis of proliferative vitreoretinopathy. *Proteomics* 8(17):3667-3678. doi:
721 10.1002/pmic.200700824.

722

723

Supplementary figures

S1 figure. Gene ontology (GO) classification of 315 salivary proteins identified in this study. The proteins were classified based on (A) subcellular localization, (B) biological processes involved and (C) molecular functions.

S2 figure. Gene ontology (GO) classification of top 20 up-regulated salivary proteins identified in this study. The proteins were classified based on (A) subcellular localization, (B) biological processes involved and (C) molecular functions.

S3 figure. Protein-protein interaction network prediction. Network (A) contains 35 proteins involved in connective tissue disorders, immunological disease and inflammatory disease in which 22 proteins were identified from the NPDR disease group. Network (B) contains 35 proteins involved in cellular movement, hematological system development and function and immune cell trafficking in which 28 proteins are identified from the PDR disease group. Network (C) contains 26 proteins involved in cellular growth and proliferation, cancer and carbohydrate metabolism in which 10 proteins are identified in PDR disease group. (ACTB = actin, cytoplasmic 1, ANXA1 = annexin A1, APOA1 = apolipoprotein A-I , CAMP = cathelicidin antimicrobial peptide, CAP1 = adenylyl cyclase-associated protein 1, CLU = clusterin, C3 = complement C3, ELANE = neutrophil elastase, ENO1 = alpha-enolase isoform 1, EZR = ezrin, GAPDH = glyceraldehyde-3-phosphate dehydrogenase isoform 2, GSN = gelsolin isoform d, HBA1/HBA2 = hemoglobin subunit alpha, HP = haptoglobin isoform 2, HSPA8 = heat shock cognate 71 kDa protein isoform 1, HSPA1A/HSPA1B = heat shock 70 kDa protein 1A/1B, LCP1 = plastin-2, , LCN1 = lipocalin-1 isoform 1, LCN2 = neutrophil gelatinase-associated lipocalin, LDHA = L-lactate dehydrogenase A chain isoform 3, LTF = lactotransferrin isoform 1, MIF = macrophage migration inhibitory factor, MMP9 = matrix metalloproteinase-9, MPO = myeloperoxidase, PKM = pyruvate kinase isozymes M1/M2 isoform c, PLTP = phospholipid transfer protein isoform a, PRDX1 = peroxiredoxin-1, PRTN3 = profilin-1, SERPINA1 = alpha-1-antitrypsin, SLPI = antileukoproteinase, S100A8 = protein S100-A8, S100A9 = protein S100-A9, TIMP1 = metalloproteinase inhibitor 1, TPM3 = tropomyosin alpha-3 chain isoform 2)

Supplementary tables

S1 table. Salivary proteins that are differentially expressed in PDR disease group compared to XDR disease group.

761 **S2 table. Salivary proteins that are differentially expressed in NPDR patient group**
762 **compared to XDR patient group.**
763
764

765 **S3 table The differentially expressed proteins identified from the study that interact with**
766 **each other in the protein-protein network analysis.**

Table 1(on next page)

Demographic of subjects.

M, Malays; I, Indian; C, Chinese; F, Female. All the pairs were compared using one-way ANOVA and Student's t-test, there no statistically significant difference (p-value all >0.05)

1 **Table 1 Demographic of subjects.**

Parameters	XDR (N=15)	NPDR (N=15)	PDR (N=15)
Age	61.8±8.77	60.63±6.49	58.94±6.98
Race (M/I/C)	7/3/5	7/5/3	9/4/2
Sex (Male/F)	5/10	7/8	8/7
Duration of diabetes (year)	12.87±4.97	13.94±7.15	14.62±5.51
HbA_{1c} (%)	7.73±1.15	8.43±1.08	8.85±1.9
Fasting blood sugar (mmol/l)	8.16±1.62	8.6±3.37	8.99±3.3
Creatinine (µg/l)	93.9±41.17	107.0±40.9	125.3±71.86

M, Malays; I, Indian; C, Chinese; F, Female.
All the pairs were compared using ANOVA and T-test, there no statistically significant difference (p-value all >0.05)

2

Table 2(on next page)

Proteins associated with NPDR and PDR that were reported in vitreous.

1 **Table 2 Proteins associated with NPDR and PDR that were reported in vitreous.**

Protein name	Saliva	Vitreous
Alpha-1-antitrypsin (SERPINA1)	Elevated in PDR	Elevated in moderate and severe PDR (Gao et al. 2008; Kanwar et al. 2009; Hazra et al. 2012)
Alpha-2-macroglobulin	Elevated in PDR	Elevated in severe PDR (Gao et al. 2008; Kanwar et al. 2009; Hazra et al. 2012)
Alpha-enolase	Elevated in PDR	Present in control and moderate PDR (Kanwar et al. 2009; Hazra et al. 2012)
Apolipoprotein A-I	Elevated in PDR	Elevated in moderate and severe PDR (Gao et al. 2008; Kanwar et al. 2009; Hazra et al. 2012)
Catalase	Elevated in PDR	Present in XDR and PDR (Gao et al. 2008; Kanwar et al. 2009)
Clusterin	Elevated in PDR	Present in vitreous (esp. moderate and severe PDR (Gao et al. 2008; Hazra et al. 2012); decreased in PDR (Kadoglou et al. 2005)
Complement C3	Elevated in PDR	Elevated in moderate PDR (Gao et al. 2008; Hazra et al. 2012)
Cystatin-C	Elevated in PDR	Present in vitreous (control, moderate and severe PDR) (Gao et al. 2008; Hazra et al. 2012)
Fructose-bisphosphate aldolase C	Elevated in PDR	Present in XDR (Gao et al. 2008)
Galectin-3-binding protein	Elevated in PDR	Elevated in severe PDR (Gao et al. 2008; Hazra et al. 2012)
Gelsolin	Elevated in PDR	Present in moderate and severe PDR (Hazra et al. 2012)
Glyceraldehyde-3-phosphate dehydrogenase	Elevated in PDR	Decreased in PDR (Kadoglou et al. 2005); present in control and moderate PDR (Hazra et al. 2012)
Haptoglobin	Elevated in PDR	Present in vitreous (esp. severe PDR) (Gao et al. 2008; Kanwar et al. 2009; Hazra et al. 2012)
Hemoglobulin subunit alpha	Elevated in PDR	Elevated in PDR (Gao et al. 2008)
Hemopexin	Elevated in PDR	Elevated in XDR (Gao et al. 2008; Kadoglou et al. 2005),32]; present in control, moderate and severe PDR (Kanwar et al. 2009; Hazra et al. 2012)
Peroxiredoxin-1	Decreased in NPDR	Elevated in PDR (Gao et al. 2008); present in control (Hazra et al. 2012)
Protein S100-A8	Elevated in PDR	Present in XDR and PDR (Gao et al. 2008)
Protein S100-A9	Elevated in PDR	Present in XDR and PDR (Gao et al. 2008)

2

1

Log ratio of relative intensity (NPDR/XDR; PDR/XDR) for proteins commonly found in XDR, NPDR and PDR disease groups.


keratin, type II cytoskeletal 6A [Homo sapiens]
histone H2A type 3 [Homo sapiens]
histone H2A type 2-C [Homo sapiens]
alpha-amylase 2B precursor [Homo sapiens]
suprabasin isoform 1 precursor [Homo sapiens]
TMEM189-UBE2V1 fusion protein [Homo sapiens]
actin, alpha skeletal muscle [Homo sapiens]
keratin, type II cytoskeletal 5 [Homo sapiens]
proline-rich protein 4 isoform 2 precursor [Homo sapiens]
ubiquitin-60S ribosomal protein L40 precursor [Homo sapiens]
alpha-1-acid glycoprotein 2 precursor [Homo sapiens]
neutrophil defensin 1 preproprotein [Homo sapiens]
metalloproteinase inhibitor 1 precursor [Homo sapiens]
hemoglobin subunit alpha [Homo sapiens]
glyceraldehyde-3-phosphate dehydrogenase isoform 2 [Homo sapiens]
phosphoglycerate mutase 1 [Homo sapiens]
pyruvate kinase isozymes M1/M2 isoform c [Homo sapiens]
cystatin-S precursor [Homo sapiens]
UPF0762 protein C6orf58 precursor [Homo sapiens]
cystatin-B [Homo sapiens]
cystatin-SN precursor [Homo sapiens]
apolipoprotein A-I preproprotein [Homo sapiens]
glutathione S-transferase P [Homo sapiens]
cystatin-SA precursor [Homo sapiens]
serpin B3 [Homo sapiens]
fructose-bisphosphate aldolase A isoform 2 [Homo sapiens]
hemoglobin subunit beta [Homo sapiens]
protein S100-A8 [Homo sapiens]
actin, cytoplasmic 1 [Homo sapiens]
immunoglobulin J chain precursor [Homo sapiens]
lipocalin-1 isoform 1 precursor [Homo sapiens]
alpha-amylase 1 precursor [Homo sapiens]
zymogen granule protein 16 homolog B precursor [Homo sapiens]
keratin, type I cytoskeletal 13 isoform a [Homo sapiens]
kallikrein-1 preproprotein [Homo sapiens]
transketolase isoform 1 [Homo sapiens]
BPI fold-containing family B member 2 precursor [Homo sapiens]
glucose-6-phosphate isomerase isoform 1 [Homo sapiens]
prolactin-inducible protein precursor [Homo sapiens]
keratin, type I cytoskeletal 10 [Homo sapiens]
carbonic anhydrase 6 isoform 1 precursor [Homo sapiens]
keratin, type II cytoskeletal 4 [Homo sapiens]
heat shock 70 kDa protein 1A/1B [Homo sapiens]
serotransferrin precursor [Homo sapiens]
lactoperoxidase isoform 1 preproprotein [Homo sapiens]
zinc-alpha-2-glycoprotein precursor [Homo sapiens]
deleted in malignant brain tumors 1 protein isoform c precursor [Homo...
polymeric immunoglobulin receptor precursor [Homo sapiens]
serum albumin preproprotein [Homo sapiens]
mucin-5B precursor [Homo sapiens]
keratin, type I cytoskeletal 16 [Homo sapiens]
macrophage migration inhibitory factor [Homo sapiens]
aldehyde dehydrogenase, dimeric NADP-preferring [Homo sapiens]
vitamin D-binding protein isoform 3 precursor [Homo sapiens]
catalase [Homo sapiens]
desmoglein-3 preproprotein [Homo sapiens]
alpha-1-antitrypsin precursor [Homo sapiens]
transaldolase [Homo sapiens]
histone H3.2 [Homo sapiens]
phospholipid transfer protein isoform a precursor [Homo sapiens]
gelsolin isoform d [Homo sapiens]
14-3-3 protein sigma [Homo sapiens]
myeloperoxidase precursor [Homo sapiens]
myeloblastin precursor [Homo sapiens]
lysozyme C precursor [Homo sapiens]
triosephosphate isomerase isoform 2 [Homo sapiens]
alpha-actinin-1 isoform c [Homo sapiens]
neutrophil elastase preproprotein [Homo sapiens]
clusterin preproprotein [Homo sapiens]
cystatin-C precursor [Homo sapiens]
heat shock cognate 71 kDa protein isoform 1 [Homo sapiens]
matrix metalloproteinase-9 preproprotein [Homo sapiens]
protein disulfide-isomerase precursor [Homo sapiens]
protein S100-A9 [Homo sapiens]
haptoglobin isoform 2 preproprotein [Homo sapiens]
BPI fold-containing family A member 2 precursor [Homo sapiens]
alpha-enolase isoform 1 [Homo sapiens]
annexin A1 [Homo sapiens]
6-phosphogluconate dehydrogenase, decarboxylating [Homo sapiens]
BPI fold-containing family B member 1 precursor [Homo sapiens]
alpha-2-macroglobulin-like protein 1 precursor [Homo sapiens]
plastin-2 [Homo sapiens]
lactotransferrin isoform 1 precursor [Homo sapiens]
-2
-1.5
-1
-0.5
0
0.5
1
1.5
2
2.5
Log ratio
NPDR/XDR
PDR/XDR

2

Log ratio of relative intensity (NPDR/XDR; PDR/XDR or proteins found exclusively in NPDR and PDR disease groups.



3

Canonical pathways comparative studies in differentially expressed proteins from NPDR and PDR groups.


NPDR/XDR
PDR/XDR
-log(p-value)
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0
Threshold
LXR/RXR Activation
Clathrin-mediated Endocytosis Signaling
Atherosclerosis Signaling
Production of Nitric Oxide and Reactive Oxygen Species in Macrophages
Role of IL-17A in Psoriasis
Glycolysis I
Gluconeogenesis I
FXR/RXR Activation
IL-12 Signaling and Production in Macrophages
Leukocyte Extravasation Signaling
Regulation of Actin-based Motility by Rho
Acute Phase Response Signaling
Actin Cytoskeleton Signaling

4

Summary of pathogenetic mechanism for non-proliferative diabetic retinopathy and proliferative diabetic retinopathy and the functional pathways involved.


Non-proliferative diabetic retinopathy
Disease progression
Proliferative diabetic retinopathy
Vascular Permeability
- Leukocyte extravasation signalling
- Regulation of actin-based motility by Rho
- Actin cyctoskeleton signalling
Inflammation
- Acute phase signalling
- IL-12 signalling and production in macrophage
Retinal ischemia
- Clathrin mediated endocyctosis signalling
- IL-12 signalling and production
Oxidative stress
- Production of nitric oxide and reactive oxygen species in macrophage
Lipid exudation
- LXR/RXR activation
- FXR/RXR activation
Neovasculation
- Regulation of actin-based motility by Rho
- Actin cytoskeleton signalling
Hyperglycemia
- Glycolysis 1
- Gluconeogenesis
Advanced glycation end-product
- Clathrin-mediated endocytosis signalling